122 related articles for article (PubMed ID: 34456124)
1. Feasibility and outcome of radical prostatectomy following inductive neoadjuvant therapy in patients with suspicion of rectal infiltration.
Hoeh B; Preisser F; Wenzel M; Humke C; Wittler C; Köllermann J; Bodelle B; Bernatz S; Steuber T; Tilki D; Graefen M; Karakiewicz PI; Becker A; Kluth LA; Chun FKH; Mandel P
Urol Oncol; 2022 Feb; 40(2):59.e7-59.e12. PubMed ID: 34456124
[TBL] [Abstract][Full Text] [Related]
2. Radical prostatectomy in T4 prostate cancer after inductive androgen deprivation: results of a single-institution series with long-term follow-up.
Hajili T; Ohlmann CH; Linxweiler J; Niklas C; Janssen M; Siemer S; Stoeckle M; Saar M
BJU Int; 2019 Jan; 123(1):58-64. PubMed ID: 29772100
[TBL] [Abstract][Full Text] [Related]
3. Optimal PSA Threshold for Androgen-Deprivation Therapy in Patients with Prostate Cancer following Radical Prostatectomy and Adjuvant Radiation Therapy.
Ahn HK; Lee KS; Kim D; Rha KH; Hong SJ; Chung BH; Koo KC
Yonsei Med J; 2020 Aug; 61(8):652-659. PubMed ID: 32734728
[TBL] [Abstract][Full Text] [Related]
4. Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases.
Heidenreich A; Fossati N; Pfister D; Suardi N; Montorsi F; Shariat S; Grubmüller B; Gandaglia G; Briganti A; Karnes RJ
Eur Urol Oncol; 2018 May; 1(1):46-53. PubMed ID: 31100228
[TBL] [Abstract][Full Text] [Related]
5. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease.
Eastham JA; Kelly WK; Grossfeld GD; Small EJ;
Urology; 2003 Dec; 62 Suppl 1():55-62. PubMed ID: 14747042
[TBL] [Abstract][Full Text] [Related]
6. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
[TBL] [Abstract][Full Text] [Related]
7. Duration of neoadjuvant androgen deprivation therapy before radical prostatectomy and disease-free survival in men with prostate cancer.
Meyer F; Bairati I; Bédard C; Lacombe L; Têtu B; Fradet Y
Urology; 2001 Aug; 58(2 Suppl 1):71-7. PubMed ID: 11502453
[TBL] [Abstract][Full Text] [Related]
8. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant Chemotherapy Using Reduced-Dose Docetaxel Followed by Radical Prostatectomy for Patients With Intermediate and High-Risk Prostate Cancer: A Single-Center Study.
Nosov A; Reva S; Petrov S; Mamijev E; Novikov R; Veliev E; Imkamp F; Tolkach Y; Moiseenko V
Prostate; 2016 Nov; 76(15):1345-52. PubMed ID: 26864707
[TBL] [Abstract][Full Text] [Related]
10. [Functional and oncological outcome of salvage prostatectomy of locally recurrent prostate cancer following radiation therapy].
Heidenreich A; Ohlmann C; Ozgür E; Engelmann U
Urologe A; 2006 Apr; 45(4):474-81. PubMed ID: 16465521
[TBL] [Abstract][Full Text] [Related]
11. Response of intraductal carcinoma of the prostate to androgen deprivation therapy predicts prostate cancer prognosis in radical prostatectomy patients.
Kato M; Hirakawa A; Kobayashi Y; Yamamoto A; Ishida R; Kamihira O; Sano T; Majima T; Ishida S; Funahashi Y; Sassa N; Fujita T; Matsukawa Y; Hattori R; Gotoh M; Tsuzuki T
Prostate; 2020 Feb; 80(3):284-290. PubMed ID: 31860754
[TBL] [Abstract][Full Text] [Related]
12. Preliminary analysis of the feasibility and safety of salvage robot-assisted radical prostatectomy after radiation failure: multi-institutional perioperative and short-term functional outcomes.
Chauhan S; Patel MB; Coelho R; Liss M; Rocco B; Sivaraman AK; Palmer KJ; Coughlin GD; Ferrigni RG; Castle EP; Ahlering TE; Parra-Davila E; Patel VR
J Endourol; 2011 Jun; 25(6):1013-9. PubMed ID: 21568696
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer.
Clark PE; Peereboom DM; Dreicer R; Levin HS; Clark SB; Klein EA
Urology; 2001 Feb; 57(2):281-5. PubMed ID: 11182337
[TBL] [Abstract][Full Text] [Related]
14. Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series.
Gandaglia G; Fossati N; Karnes RJ; Boorjian SA; Colicchia M; Bossi A; Seisen T; Cozzarini C; Di Muzio N; Noris Chiorda B; Zaffuto E; Wiegel T; Shariat SF; Goldner G; Joniau S; Battaglia A; Haustermans K; De Meerleer G; Fonteyne V; Ost P; Van Poppel H; Montorsi F; Briganti A
Eur Urol; 2018 Apr; 73(4):512-518. PubMed ID: 29229176
[TBL] [Abstract][Full Text] [Related]
15. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome.
Ward JF; Slezak JM; Blute ML; Bergstralh EJ; Zincke H
BJU Int; 2005 Apr; 95(6):751-6. PubMed ID: 15794776
[TBL] [Abstract][Full Text] [Related]
16. Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade.
McKay RR; Montgomery B; Xie W; Zhang Z; Bubley GJ; Lin DW; Preston MA; Trinh QD; Chang P; Wagner AA; Mostaghel EA; Kantoff PW; Nelson PS; Kibel AS; Taplin ME
Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):364-372. PubMed ID: 29263420
[TBL] [Abstract][Full Text] [Related]
17. Long-term survival of patients with locally advanced prostate cancer managed with neoadjuvant docetaxel and radical prostatectomy.
Zhao B; Yerram NK; Gao T; Dreicer R; Klein EA
Urol Oncol; 2015 Apr; 33(4):164.e19-23. PubMed ID: 25665510
[TBL] [Abstract][Full Text] [Related]
18. The survival impact of neoadjuvant hormonal therapy before radical prostatectomy for treatment of high-risk prostate cancer.
Tosco L; Laenen A; Briganti A; Gontero P; Karnes RJ; Albersen M; Bastian PJ; Chlosta P; Claessens F; Chun FK; Everaerts W; Gratzke C; Graefen M; Kneitz B; Marchioro G; Salas RS; Tombal B; Van den Broeck T; Moris L; Battaglia A; van der Poel H; Walz J; Bossi A; De Meerleer G; Haustermans K; Van Poppel H; Spahn M; Joniau S
Prostate Cancer Prostatic Dis; 2017 Dec; 20(4):407-412. PubMed ID: 28485390
[TBL] [Abstract][Full Text] [Related]
19. The limited significance of a longer duration of neoadjuvant hormonal therapy prior to radical prostatectomy for high-risk prostate cancer in Japanese men.
Miyake H; Sakai I; Inoue TA; Hara I; Fujisawa M
Urol Int; 2006; 77(2):122-6. PubMed ID: 16888415
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant Androgen Deprivation Therapy Prior to Radical Prostatectomy: Recent Trends in Utilization and Association with Postoperative Surgical Margin Status.
McClintock TR; von Landenberg N; Cole AP; Lipsitz SR; Gild P; Sun M; Fletcher SA; Roghmann F; Menon M; Nguyen PL; Noldus J; Choueiri TK; Kibel AS; Trinh QD
Ann Surg Oncol; 2019 Jan; 26(1):297-305. PubMed ID: 30430324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]